Background. Before highly active antiretroviral therapy (HAART), congenital cytomegalovirus (CMV) rates were higher among human immunodeficiency virus (HIV)-exposed infants than unexposed infants. This study examines congenital and perinatal/early postnatal (P/EP) CMV among HIV-exposed infants pre-and post-HAART.
breast milk containing CMV become postnatally infected with CMV, with a higher risk of symptomatic CMV among preterm infants [4, 5] . CMV reactivation in breast milk without shedding in maternal urine, saliva, or blood during lactation has also been noted [6] .
In nonbreastfeeding women, perinatal CMV (transmission during birth from exposure to cervical and vaginal secretions) and early postnatal CMV (transmission through continued exposure to mother's saliva or other secretions through age 6 months) are important routes of mother-to-infant CMV transmission [5, 7] . Depending on the population, 2%-28% of seropositive mothers shed CMV in cervical and vaginal secretions during delivery, and 40%-50% of their exposed infants are infected [5, 7, 8] . Among HIV-infected women, shedding rates have similarly varied, with rates as high as 59% in Kenyan women [9] [10] [11] [12] . Cervical CMV shedding was associated with HIV cervical shedding, HIV viral load, and decreasing CD4 cell counts, suggesting the importance of a weakened immune system in coinfected women [10] [11] [12] .
Perinatal/postnatal CMV infection results in chronic viral excretion persisting for years [2, 7, 13] . Although its sequelae are less severe than those of congenital infection, higher-risk infants (ie, preterm or HIV exposed) may develop hearing loss and clinical illnesses such as pneumonia, hepatitis, hepatosplenomegaly, anemia, thrombocytopenia, and abnormal hepatic function [2, 8, 14, 15] . Increased CMV-associated morbidity was noted in HIV-exposed infants in Africa [16] .
Before the advent of highly active antiretroviral therapy (HAART) for HIV infection, congenital CMV rates were high (2.7%-6.5%) among HIV-exposed newborns [17] [18] [19] . A recent study of congenital CMV post-HAART showed rates remaining high among HIV-infected infants but decreasing for HIVexposed uninfected infants [20] . No studies have examined the impact of prenatal HAART on the frequency and morbidity of perinatal/early postnatal (P/EP) CMV in HIV-exposed newborns.
We investigated pre-and post-HAART prevalence rates of congenital and P/EP CMV among infants born during 1988-2002 to nonbreastfeeding, HIV-infected mothers and seen before 7 months of age at our Maternal, Child and Adolescent Center for Infectious Diseases and Virology (MCA) in Los Angeles County (LAC), California. Even in the earlier years of the HIV epidemic, the US recommendation for HIV-positive mothers was not to breastfeed their infants. Neonatal CMV testing was recommended for all infants born to HIV-infected women in our clinic.
MATERIALS AND METHODS

Study Population
The MCA clinic is a comprehensive care center for HIVinfected women and their families. The clinic serves those with no or limited healthcare options and is LAC's largest referral site for HIV-infected pregnant women and their children. Informed consent was obtained for mothers and their newborns to participate in the University of Southern California institutional review board-approved natural history study to obtain clinical and laboratory data. Infant CMV assessments were done at routine clinic appointments. With the 1994 National Institutes of Health announcement of ACTG 076 trial results showing that antiretroviral treatment (ART) given to the mother during pregnancy, labor, and delivery and to the newborn 6 weeks postpartum prevented vertical transmission, ART became our standard of care. In 1997, HAART became our recommended regimen for HIV-positive pregnant women. All newborns received 6 weeks of zidovudine, and the recommendation at that time was for mothers to remain on HAART postpartum.
Infants born during 1988-2002 to HIV-infected women seen in our clinic were eligible for this study if they had ≥1 CMV culture during their first 6 months of life. Laboratory results were entered into the Natural History Database and clinical data were collected from 6-month medical chart reviews from birth. Laboratory testing was performed in the LAC + USC Medical Center laboratory.
CMV Culture
Urine was collected from a nurse-applied bag, and oral swabs of the inner cheek were collected by the clinic nurse. CMV cultures were performed using standard virologic techniques, either tube culture or rapid shell-vial.
Maternal CMV Serological Status
Serological tests for maternal CMV were performed as part of the TORCH series during pregnancy. A mother was considered CMV seropositive if ≥1 CMV immunoglobulin G (IgG) test or immunoglobulin M was positive before or at the child's birth. A mother was considered CMV seronegative if there was no prior positive CMV test and the IgG test closest to delivery was negative. During the study period, CMV status was available for 281 of 414 mothers, and 272 (97%) were positive.
Newborn HIV Infection Status
HIV diagnosis was made by the detection of HIV type 1 antibody by enzyme-linked immunosorbent assay and Western blot in children ≥18 months of age. Children <18 months were diagnosed by a positive HIV DNA polymerase chain reaction (PCR) assay (in peripheral blood mononuclear cells by Ficoll separation until 1995 and in whole blood extraction after 1995) on 2 separate occasions, with one assay performed after the 6-week neonatal prophylactic treatment. PCR testing was performed at birth, 2-4 weeks, 6 weeks to 2 months, and 4, 6, 12, and 18 months.
Variables
Demographic and birth characteristics recorded included maternal age, race/ethnicity, gestational age, injection drug use (IDU), mode of delivery, use of HAART during pregnancy (defined here as triple ART with ≥1 nonnucleoside reversetranscriptase inhibitor or protease inhibitor), any prenatal ART, plasma HIV viral load, and CD4 cell count measured closest to delivery; and child's birth weight, sex, and HIV status. Symptoms lasting >1 month during the first year of life, including failure to thrive, lymphadenopathy, splenomegaly, hepatomegaly, anemia, thrombocytopenia, or neurologic impairment, were recorded. Congenital CMV was defined as a positive urine or oral culture within the first 3 weeks of life. P/EP infection was defined as a positive culture in the first 6 months of life, excluding those with congenital infection. One or more negative test result at >3 weeks of age in the absence of a positive test defined the child as negative for P/EP CMV infection.
Statistical Analyses
The prevalence of CMV infection was compared across the independent variables of interest using χ 2 test for categorical variables and Student t test for continuous variables. Multivariate analyses used logistic regression. An independent variable was included in the multivariate model if the P value for the corresponding univariate model was <.10. A P value < .05 was considered statistically significant. SAS software, version 9.2, was used for all statistical analyses.
RESULTS
Characteristics of the Infant Population
During 1988-2002, 444 infants were seen before 7 months of age; 414 (93%) had a CMV assessment and were included in this study ( Figure 1 ). There were no statistically significant differences between infants with and those without a CMV assessment by sex, age first seen, race, or HIV status, although those born before 1997 were more likely to be included than those born later (96% vs 91%, respectively; P < .05). Of the 414 infants in the study, 339 were seen before 21 days of age and 248 (73%) had ≥1 CMV assessment during this period. More than half the infants had both congenital and P/EP assessments. An additional 166 had a P/EP assessment only. There were no statistically significant differences between those with a congenital assessment and those without by birth cohort, prematurity, or HIV status, although those born at our facility (P = .06) and those with a nursery stay ≤7 days (P < .05) were more likely to have an assessment. A total of 393 were evaluated for P/EP CMV infection. Oral and urine assessments were completed on the same day for 586 assessment days, and 97% of the results were in agreement. There were 5 of 54 assessment days positive by oral test but negative by urine test and 14 of 63 positive by urine test but negative by oral test. A total of 1678 CMV assessment days were completed, with a mean of 3 assessment days per child (range, 1-15). In total, 2264 tests were completed including 832 urine tests (12% positivity) and 1432 oral tests (9% positivity).
Demographic and birth characteristics of the study infants are shown in Table 1 for 2 study periods defined by when HAART become standard of care. Overall, 62% of infants were Hispanic and 31% were black, 21% were premature, mean birth weight was 3131 grams, and mother's mean age at delivery was 28 years. About half of the infants were born in each of the 2 study periods. From the pre-HAART era to the post-HAART era, the proportion of males and cesarean deliveries increased, and the proportion of HIV-infected infants and IDU mothers decreased. During 1988-1996, 1% of mothers received HAART and 32% received ART during their pregnancy; during 1997-2002, the corresponding percentages were 77% and 88%.
Prevalence of Congenital CMV Infection
Among the 248 infants with a CMV test during the congenital period, 3.6% were CMV positive, for a prevalence rate of 3600 infections per 100 000 live births (95% CI, 1942-6750 per 100 000 live births) ( Table 2 ). The prevalence did not differ significantly over the 2 time periods by infant's HIV status, maternal HAART or ART use, or any of the demographic or birth characteristics examined. Among the 9 children with congenital infection, symptoms were observed in 2. Neither child had maternal ART: 1 was HIV-infected and had lymphadenopathy and hepatosplenomegaly, and 1 was coinfected with congenital toxoplasmosis and had lymphadenopathy, hepatosplenomegaly, and failure to achieve developmental milestones with Mother not receiving prenatal antiretroviral therapy was the only variable significantly associated with perinatal/postnatal cytomegalovirus in the multivariate logistic regression analysis controlling for all other variables with a P value < .10 (OR = 4.7 [95% CI, 1.6-13.8]).
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CMV, cytomegalovirus; CMV+, CMV positive; CMV-, CMV negative; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; IDU, injection drug use; OR, odds ratio.
long-term neurologic impairments. Among 7 with hearing evaluations noted in the first 6 months, none had abnormalities. None had abnormal head computed tomography, ultrasonography, or magnetic resonance imaging results.
Prevalence of P/EP CMV Infection
The 393 infants with ≥1 P/EP CMV test (27 infants had only 1 test) had a mean number of 4 assessment days at a mean age of 149 days. Fifty-two infants were CMV positive (median age, 64 days) with a prevalence of P/EP CMV infection of 13.2% or 132 infections per 1000 live births (95% CI, 102-169 per 1000 live births). The prevalence significantly decreased from 17.9% in 1988-1996 to 8.9% in 1997-2002 (P < .01). Similarly, HIV-infected infants had higher rates than those who were HIV uninfected, and whites had higher rates than nonwhites. Children without maternal ART were 2.4 times more likely to be CMV positive than those with maternal ART. This trend was also seen for mothers not on HAART versus on HAART, children delivered vaginally versus cesarean delivery, and mothers with a CD4 count ≤200 cells/μL versus >200 cells/μL, but statistical significance was not reached. In the multivariate model, mothers without ART were significantly associated with P/EP CMV (odds ratio [OR] = 4.7 [95% confidence interval {CI}, 1.6-13.8]) when controlling for race, birth cohort, HIV status, delivery mode, and maternal CD4 status, with all other variables not significant.
Factors Associated With P/EP CMV Infection for Infants Without Maternal ART or HAART
For infants without maternal ART, P/EP CMV rates were greater for the HIV infected, those delivered vaginally, and those whose mother's CD4 count was ≤200 cells/μL (Table 3 ).
In the final multivariate analysis, only mothers with a CD4 count ≤200 cells/μL remained significantly associated with P/EP CMV (OR = 8.8 [95% CI, 1.9-40.7]), controlling for mode of delivery and HIV status. Among the 43 HIV-uninfected infants with P/EP CMV, those without maternal HAART were more likely to have symptoms associated with P/EP (41%) than those with maternal HAART (6%) (OR = 10.3 [95% CI, 1.2-89.9]). Eleven HIV-uninfected children without maternal HAART had symptoms including anemia (n = 5), thrombocytopenia (n = 1), hepatomegaly (n = 1), lymphadenopathy (n = 7), impaired brain growth (n = 2), acquired microcephaly or failure to progress or achieve new milestones (n = 1), and failure to thrive (n = 1). One HIV-uninfected child with HAART had anemia. No HIV transmissions occurred among mothers who received ART or HAART. All 9 HIVinfected infants with P/EP CMV had symptoms that could have been due to either their HIV, CMV, or both. 
DISCUSSION
In this study of children born to nonbreastfeeding, HIV-infected mothers during 1988-2002 and cared for in Los Angeles, California, several changes were observed over time.
Simultaneous with the onset of HAART was an observed decrease in the number and proportion of HIV-infected children, demonstrating the success of HAART in decreasing maternal-child HIV transmission. There was also an increase in cesarean deliveries and maternal age, and a decrease in IDU mothers. The prevalence of congenital CMV was 3.6%, with no statistically significant difference by birth cohort and thus no observed impact of HAART use. A similarly high rate (3%) was reported in a HAART-treated cohort in Texas [21] . Even for the 276 babies born at our hospital in 2003-2010 with CMV data available in the first 3 weeks of life, we observed a prevalence of 4.0% (data not shown). The large French Perinatal Cohort Study, however, reported a declining rate of congenital CMV among HIV-exposed uninfected infants [20] , particularly if HAART began in the first trimester compared to the second or third trimester. Our congenital CMV rates may be higher because a majority of our mothers were identified as HIV-infected during pregnancy and referred to our clinic after their first trimester.
We did, however, observe a decline in P/EP CMV from the pre-HAART to the post-HAART era from 17.9% to 8.9%, concurrent with a decline in perinatal HIV infection, an increase in cesarean delivery rates, and an increase in ART and prenatal HAART. Stratification on mother's receipt of ART showed that risk factors for P/EP CMV were apparent only for infants without maternal ART. For those without ART, the prevalence increased for those whose mother's CD4 count was ≤200 cells/μL even while controlling for HIV status, suggesting that without ART, the risk of P/EP CMV transmission increased because of less effective control of the mother's immunologic status, most likely resulting in increased mucosal shedding. With better immunologic control during pregnancy, the quantity of virus is reduced and mucosal shedding is likely decreased so that transmission during the birth process is reduced [22] . With viral control after delivery, the mother may be at lower risk of mucosal CMV shedding [23] . Review of the 52 infants with P/EP CMV showed that none were known to have been breastfed. Although not recommended, some women discontinued ART after delivery. Of 115 mothers with data, those stopping were more likely to transmit (27%) virus than those continuing (13%), although statistical significance was not attained most likely owing to limited sample size.
Among children with P/EP CMV whose mother received HAART (n = 16), 1 had anemia. Among those whose mothers did not receive HAART, CMV-related symptoms occurred in 41% of the HIV-uninfected infants and 100% of the HIVinfected infants. A higher rate of symptomatology among HIV-infected infants has been reported, but the rate among HIV-uninfected infants is higher than that in studies of non-HIV-exposed infants [24] [25] [26] .
This study has several limitations. First, CMV assessments were not done consistently for all newborns because many were first seen after the newborn period. However, analyses of infants with and without a congenital assessment showed no selection process for higher-risk infants to be evaluated. Second, further stratified analyses were limited by the small number of congenitally infected infants. Third, the exact timing of CMV infection could not be determined. It is difficult to differentiate whether CMV infection was acquired congenitally, perinatally, or postnatally in infants after 3 weeks of age unless there was a negative culture before 3 weeks or the presence of certain clinical features such as chorioretinitis, intracranial calcification, microcephaly, or hearing loss, which were not consistently measured in this study [2] . PCR can also be useful in diagnosing P/EP CMV but was not done in this study [5] . For the 166 infants with a P/EP assessment only, congenital infection cannot be excluded. Analyses restricted to infants with test results during both the congenital and P/EP periods, however, showed the same associations. Fourth, some infants could have been infected from older siblings, although studies have demonstrated that mothers are the main source of P/EP CMV infection [27] . Fifth, an HIV-unexposed comparison group was not included to assess the high levels of symptomatic P/EP CMV among the HIV-uninfected infants.
Our findings have important implications for women and children worldwide, especially in areas where treatment of all HIV-infected pregnant women is not the standard of care. The benefits of treatment may be seen in reducing not only HIV mother-to-infant transmission, but also the incidence of P/EP CMV and its associated morbidity, especially for highrisk infants. HIV-exposed but uninfected children with acute CMV infections may be an emerging group in Africa [28] . It is unknown if more extensive HAART during pregnancy, limiting breastfeeding duration, or continuing HAART during breastfeeding could reduce rates of postnatal CMV, reduce CMV viral loads, and reduce symptoms. Because P/EP infections are much more prevalent than congenital infections and go undiagnosed, they represent a major public health problem worldwide, especially in HIV-endemic areas [13, 14] . Improving the HIV-infected mother's health through prenatal care and ART or HAART could improve maternal immunity, resulting in decreased rates and quantity of mucosal shedding of CMV during birth as well as postpartum. Improved maternal health may also reduce the incidence of reinfection and reactivation and the subsequent incidence of P/EP infection even in breastfeeding populations.
The vast majority of the mothers in our study were CMV seropositive, and mother-to-child transmission was likely due to reactivation of latent CMV infection during pregnancy or possibly reinfection. A Finnish study found no infant infections in seronegative mothers, suggesting that P/EP infection is strongly related to the mother's CMV status and not close contact with other children [29] . Even among breastfeeding women, CMV infection acquired during delivery can be an important route of transmission [7] .
This study is novel in its examination of the prevalence of P/EP CMV infection in HIV-infected and HIV-exposed uninfected infants in a nonbreastfed population in the post-HAART era. Although the risk of severe sequelae is lower, P/EP CMV can cause serious problems. While these are common in HIV-infected children, we observed an increased risk of these symptoms in HIV-uninfected infants with P/EP CMV whose mothers had no prenatal HAART. This strongly suggests that strategies that have proven successful for preventing mother-to-child HIV transmission in nonbreastfed populations are also efficient at preventing P/EP CMV.
